ClinicalTrials.gg
CompletedNCT00150345IDEAUpdated Jan 19, 2012Results posted

Immediate vs. Deferred Empirical Antifungal Treatment With Voriconazole In Neutropenic Patients

A Phase 3 interventional study of voriconazole (Vfend) and voriconazole (Vfend) in Possible Fungal Infection, sponsored by Pfizer. Completed at 28 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-01-19.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
147
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Neutropenia with a site in Germany — 2 open to participants now, 2 under way, 1 of them phase 3. Neutropenia · Germany.

Enrollment
7th of 13
147 · median 147
Started
2005
with 1 other
Phase 3
6 of 15
1 open now
Registered
5th of 15
by date
Lead sponsor
1 of 15
Pfizer

Among the 15 studies in Neutropenia with a site in Germany, this one is the 7th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2005, is one of 6 in phase 3, and was the 5th registered.

Neutropenia

316 studies on the registry are indexed under Neutropenia; 42 are open to participants now.

Browse Neutropenia studies →

Open to participants now

2 of the 15 studies in Neutropenia with a site in Germany are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 24 Neutropenia studies recruiting now, 12 (50%) set no upper age limit and 12 (50%) stop at 75 or younger; 11 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Neutropenia with a site in Germany, or all of them as a file.
02

Study summary

A well-known side-effect of cytostatics (drugs against malignancies) is a decrease in the number of white blood cells, especially of the so-called neutrophil granulocytes, which are very important for the defense against infections. Hence their decrease (called "neutropenia") leads to a predisposition to infections.

Since infections during neutropenia can be very dangerous, the patients are treated with antibiotics from the very first signs of such an infection (usually fever). If the antibiotics (drugs against bacteria) do not lead to a normalization of the body temperature within four days, a drug against fungi is added.

In the IDEA study, one half of the patients receive the antifungal drug voriconazole (as usual) only in case the antibiotics alone do not lead to a normalization of the body temperature (current standard of care). The other half of the patients receive voriconazole immediately after onset of fever (concomitantly with the antibiotics).

The research question is, whether in the "early-treatment" group fewer manifest fungal infections will be observed than in the "late-treatment" group.

03

Conditions studied

  • Possible Fungal Infection

Keywords

  • Neutropenia
  • Fever of unknown origin
  • Empirical treatment
  • Voriconazole
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Acute leukemia, aggressive lymphoma, bone marrow or stem cell transplantation;
  • Neutropenia (\<500 neutrophils/µL) of at least 10 days;
  • Newly diagnosed fever;
  • Positive panfungal polymerase chain reaction assay

Exclusion criteria

Exclusion Criteria:

  • Documented bacterial infection during screening or at randomization
  • Fungemia or other documented invasive fungal infection during screening or at randomization.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
147 participants (actual)

Study arms

  • Experimental
    Early treatment

    Voriconazole starts within 18 hours of onset of fever intravenously with a loading dose of 6 mg/kg q12h for the first two doses followed by 4 mg/kg q12h (maintenance dose). Switched to oral treatment (200 mg BID) is possible after at least four days. Treatment will be ended if the patient is afebrile (\< 38.0 °C) for 7 days with neutrophil counts \< 500/µL, or if the patient is afebrile (\< 38.0 °C) for 2 days with neutrophil counts \> 500/µL.

    Drug: voriconazole (Vfend)

  • Other
    Deferred treatment

    Treatment with voriconazole (for dosage see "early treatment arm") is initiated only if a patient is persistently febrile on day 5 after the onset of fever despite antibiotic treatment.

    Drug: voriconazole (Vfend)

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Proven or Probable Invasive Fungal Infections (IFI): Complete Case Analysis

    Number of participants with proven (deep tissue infection, fungemia, or endemic fungal infections) or probable IFI (at least 1 host criterion \[fever, body temperature \<36 or \>38 degrees Celsius, graft-versus-host disease, use of corticosteroids\]; and 1 microbiological criterion \[fungal or yeasts\]; or clinical criteria \[abnormal site consistent with infection\]) as defined by European Organization for Research and Treatment of Cancer Mycosis Study Group (EORTC/MSG) criteria. Complete case analysis: must be evaluable until Day 28 or had developed a proven or probable IFI by the final visit.

    Time frame: Day 2 through Day 28

Secondary outcomes

  1. Number of Participants With Defervescence Day 5 (4 Days After Initiation of Study Treatment)

    Number of participants who achieved defervescence (were afebrile). Defervescence stated if all of a participants's body temperatures within 24 hours of evaluation time were \<38.0 degrees C. Defervescence was not stated and participant was discontinued from the study if participant received antipyretics (non-steroidal anti-inflammatory drugs or paracetamol).

    Time frame: Day 5 (96 hours through 120 hours after start of study treatment)

  2. Number of Participants With Defervescence Day 9 (8 Days After Initiation of Study Treatment)

    Number of participants who achieved defervescence (were afebrile). Defervescence stated if all of a participant's body temperatures within 24 hours of evaluation time were \<38.0 degrees C. Defervescence was not stated and participant was discontinued from the study if participant received antipyretics (non-steroidal anti-inflammatory drugs or paracetamol).

    Time frame: Day 9 (192 hours through 216 hours after start of study treatment)

  3. Time to Continuous Defervescence

    Time (in days) from start of study medication to continuous defervescence. Continuous defervescence stated if participant maintains a body temperature of \<38.0 degrees C for at least 96 hours.

    Time frame: Day 2 through Day 28

  4. Number of Participants Per Reason for Lack of Defervescence

    Time frame: Day 2 through Day 28

  5. Number of Participants That Died on or Before Day 28 (Mortality)

    Number of participants that died on or before Day 28 after start of study treatment. A participant must be evaluable until Day 28 (final visit) or have died before the final visit.

    Time frame: Day 2 through Day 28

  6. Time to Negative Panfungal Polymerase Chain Reaction (PCR)

    Time (in days) from start of study medication to negative panfungal PCR; assessed for participants whose most recent panfungal PCR result prior to start of study medication was positive. Defined as negative if at least 2 successive and all following panfungal PCR assessments from start of study medication until 24 hours after end of treatment are negative. Measured as first quartile of time (point in time measurement; no median or measure of dispersion calculated); median time was not estimable for deferred voriconazole treatment group.

    Time frame: Day 2 through Day 28

  7. Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association of Positive PCR Assessments With Achievement of Continuous Defervescence (Yes)

    Percent of positive panfungal PCR assessments during treatment phase of study in association with achievement of continuous defervescence (response=Yes). Continuous defervescence stated if participant maintains a body temperature of \<38.0 degrees C for at least 96 hours. Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.

    Time frame: Day 2 through Day 28

  8. Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association of Positive PCR Assessments With Achievement of Continuous Defervescence (No)

    Percent of positive panfungal PCR assessments during treatment phase of study in association with achievement of continuous defervescence (response=No). Continuous defervescence stated if participant maintains a body temperature of \<38.0 degrees C for at least 96 hours. Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.

    Time frame: Day 2 through Day 28

  9. Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Age

    Percent of positive panfungal PCR assessments during treatment phase of study in association with age for participants who completed the study and have a non-missing value for percent of positive panfungal PCR.

    Time frame: Day 2 through Day 28

  10. Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Gender

    Percent of positive panfungal PCR assessments during treatment phase of study in association with gender (Female or Male). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.

    Time frame: Day 2 through Day 28

  11. Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Primary Underlying Neoplastic Disease

    Percent of positive panfungal PCR assessments during treatment phase of study in association with primary underlying neoplastic disease. Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.

    Time frame: Day 2 through Day 28

  12. Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Planned Allogeneic Transplants

    Percent of positive panfungal PCR assessments during treatment phase of study in association with allogeneic bone marrow transplant or allogeneic peripheral stem cell transplant (Yes or No). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.

    Time frame: Day 2 through Day 28

  13. Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Concomitant Fluconazole

    Percent positive panfungal PCR assessments during treatment phase of study in association with use of concomitant (prophylaxis) fluconazole (Yes or No). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.

    Time frame: Day 2 through Day 28

  14. Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Neutrophil Count >500 uL

    Percent of positive panfungal PCR assessments during treatment phase of study in association with neutrophil count \>500 uL (Yes or No). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.

    Time frame: Day 2 through Day 28

  15. Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With C-reactive Protein Level >1.25 Times the Upper Limit of Normal (x ULN)

    Percent of positive panfungal PCR assessments during treatment phase of study in association with c-reactive protein level (measured in milligrams per liter \[mg/L\]) \>1.25 x ULN (Yes or No). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.

    Time frame: Day 2 through Day 28

  16. Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Fungal Species Identified

    Percent of positive panfungal PCR assessments during treatment phase of study in association with fungal species (singular \[one species\]=sp; plural \[many species\]=spp) identified (Yes or No). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.

    Time frame: Day 2 through Day 28

  17. Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Fungal Species Identified (Aspergillus Spp=Yes)

    Percent of positive panfungal PCR assessments during treatment phase of study in association with fungal species (singular \[one species\]=sp; plural \[many species\]=spp) identified (Yes). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.

    Time frame: Day 2 through Day 28

  18. Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Proven or Probable IFI (Complete Cases) Between Day 2 and Day 28

    Percent of positive panfungal PCR assessments during treatment phase of study in association with proven or probable IFI (complete cases) between Day 2 and Day 28 (Yes or No). Complete case analysis: participant must be evaluable until Day 28 (final visit) or have developed a proven or probable IFI by the final visit. Participant considered evaluable until Day 28 if participant completed the study and completed an assessment of IFI at Day 28 or final visit. Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.

    Time frame: Day 2 through Day 28

  19. Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Defervescence Day 5 (4 Days After Initiation of Study Treatment)

    Percent of positive panfungal PCR assessments during treatment phase of study in association with defervescence (were afebrile) Day 5 (Yes or No). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.

    Time frame: Day 5 (96 hours through 120 hours after start of study treatment)

  20. Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Defervescence (Yes) by Day 9 (8 Days After Initiation of Study Treatment)

    Percent of positive panfungal PCR assessments during treatment phase of study in association with defervescence (were afebrile) Day 9 (Yes). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.

    Time frame: Day 2 through Day 9 (192 hours through 216 hours after start of study treatment)

  21. Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Defervescence (No) by Day 9 (8 Days After Initiation of Study Treatment)

    Percent of positive panfungal PCR assessments during treatment phase of study in association with defervescence (were afebrile) Day 9 (No). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.

    Time frame: Day 2 through Day 9 (192 hours through 216 hours after start of study treatment)

  22. Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Time to Defervescence

    Percent of positive panfungal PCR assessments during treatment phase of study in association with time to defervescence. Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.

    Time frame: Day 2 through Day 28

  23. Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Reasons for Lack of Continuous Defervescence (No)

    Percent of positive panfungal PCR assessments during treatment phase of study in association with lack of continuous defervescence (No). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.

    Time frame: Day 2 through Day 28

  24. Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Reasons for Lack of Continuous Defervescence: Unknown Infection (Yes)

    Percent of positive panfungal PCR assessments during treatment phase of study in association with lack of continuous defervescence (Yes). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.

    Time frame: Day 2 through Day 28

  25. Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Mortality by Day 28 (Alive)

    Percent of positive panfungal PCR assessments during treatment phase of study in association with mortality on or before Day 28 after start of study treatment (Alive). A participant must be evaluable until Day 28 (final visit).

    Time frame: Day 2 through Day 28

  26. Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Mortality by Day 28 (Died)

    Percent of positive panfungal PCR assessments during treatment phase of study in association with mortality on or before Day 28 after start of study treatment (Died). A participant must have died before Day 28 (final visit).

    Time frame: Day 2 through Day 28

  27. Number of Participants Assessed as Needing Further Antineoplastic Therapy as Planned

    Time frame: Day 28

  28. Number of Participants With Reasons Why Antineoplastic Therapy Not Continued as Planned

    Time frame: Day 28

07

Results

Posted Aug 18, 2010
Limitations and caveats
One participant in the Immediate Voriconazole treatment group was incorrectly included in the original Primary efficacy analysis and has now been excluded; IFI was identified on the day study treatment started (not prior to study treatment).

Participant flow

810 participants screened; 81 assigned to immediate voriconazole treatment and 66 to deferred voriconazole treatment. Study should be considered a pilot study; planned sample size (n=200) was not based on statistical power considerations.

Participant flow — Overall Study
MilestoneImmediate VoriconazoleDeferred Voriconazole Treatment
Started8166
Completed4734
Not completed3432
Withdrew: Death52
Withdrew: Adverse event86
Withdrew: Lack of efficacy54
Withdrew: Withdrawal by subject34
Withdrew: Laboratory abnormality12
Withdrew: Other1214

Outcome measures

PrimaryNumber of Participants With Proven or Probable Invasive Fungal Infections (IFI): Complete Case Analysis

Number of participants with proven (deep tissue infection, fungemia, or endemic fungal infections) or probable IFI (at least 1 host criterion \[fever, body temperature \<36 or \>38 degrees Celsius, graft-versus-host disease, use of corticosteroids\]; and 1 microbiological criterion \[fungal or yeasts\]; or clinical criteria \[abnormal site consistent with infection\]) as defined by European Organization for Research and Treatment of Cancer Mycosis Study Group (EORTC/MSG) criteria. Complete case analysis: must be evaluable until Day 28 or had developed a proven or probable IFI by the final visit.

Time frame:
Day 2 through Day 28
Reported as:
Number · participants
Number of Participants With Proven or Probable Invasive Fungal Infections (IFI): Complete Case Analysis
participantsImmediate VoriconazoleDeferred Voriconazole Treatment
Number of Participants With Proven or Probable Invasive Fungal Infections (IFI): Complete Case Analysis69
Statistical analysis
  • Immediate Voriconazole vs Deferred Voriconazole Treatment · Regression, Logistic · p = 0.258 · Odds ratio (or): 0.493 · 95% CI 0.129 to 1.755Odds ratio computed from the logistic regression (logit model) including terms for treatment arm, concomitant fluconazole, and positive PCR before randomization. Event IFI=yes is modeled.
SecondaryNumber of Participants With Defervescence Day 5 (4 Days After Initiation of Study Treatment)

Number of participants who achieved defervescence (were afebrile). Defervescence stated if all of a participants's body temperatures within 24 hours of evaluation time were \<38.0 degrees C. Defervescence was not stated and participant was discontinued from the study if participant received antipyretics (non-steroidal anti-inflammatory drugs or paracetamol).

Time frame:
Day 5 (96 hours through 120 hours after start of study treatment)
Reported as:
Number · participants
Number of Participants With Defervescence Day 5 (4 Days After Initiation of Study Treatment)
participantsImmediate VoriconazoleDeferred Voriconazole Treatment
Number of Participants With Defervescence Day 5 (4 Days After Initiation of Study Treatment)3228
Statistical analysis
  • Immediate Voriconazole vs Deferred Voriconazole Treatment · Regression, Logistic · p = 0.596 · Odds ratio (or): 0.822 · 95% CI 0.398 to 1.696Odds ratio computed from the logistic regression (logit model) including terms for treatment arm, concomitant fluconazole, and positive PCR before randomization. Event defervescence=yes is modeled.
SecondaryNumber of Participants With Defervescence Day 9 (8 Days After Initiation of Study Treatment)

Number of participants who achieved defervescence (were afebrile). Defervescence stated if all of a participant's body temperatures within 24 hours of evaluation time were \<38.0 degrees C. Defervescence was not stated and participant was discontinued from the study if participant received antipyretics (non-steroidal anti-inflammatory drugs or paracetamol).

Time frame:
Day 9 (192 hours through 216 hours after start of study treatment)
Reported as:
Number · particpants
Number of Participants With Defervescence Day 9 (8 Days After Initiation of Study Treatment)
particpantsImmediate VoriconazoleDeferred Voriconazole Treatment
Number of Participants With Defervescence Day 9 (8 Days After Initiation of Study Treatment)4234
Statistical analysis
  • Immediate Voriconazole vs Deferred Voriconazole Treatment · Regression, Logistic · p = 0.864 · Odds ratio (or): 0.936 · 95% CI 0.441 to 1.988Odds ratio computed from the logistic regression (logit model) including terms for treatment arm, concomitant fluconazole, and positive PCR before randomization. Event defervescence=yes is modeled.
SecondaryTime to Continuous Defervescence

Time (in days) from start of study medication to continuous defervescence. Continuous defervescence stated if participant maintains a body temperature of \<38.0 degrees C for at least 96 hours.

Time frame:
Day 2 through Day 28
Reported as:
Median · days
Time to Continuous Defervescence
daysImmediate VoriconazoleDeferred Voriconazole Treatment
Time to Continuous Defervescence6.0 (4.0 to 8.0)5.0 (4.0 to 7.0)
Statistical analysis
  • Immediate Voriconazole vs Deferred Voriconazole Treatment · Log Rank · p = 0.955
SecondaryNumber of Participants Per Reason for Lack of Defervescence
Time frame:
Day 2 through Day 28
Reported as:
Number · participants
Number of Participants Per Reason for Lack of Defervescence
participantsImmediate VoriconazoleDeferred Voriconazole Treatment
Fungal infection33
Bacterial infection76
Viral infection10
Unknown44
Other33
Missing evaluation response01
SecondaryNumber of Participants That Died on or Before Day 28 (Mortality)

Number of participants that died on or before Day 28 after start of study treatment. A participant must be evaluable until Day 28 (final visit) or have died before the final visit.

Time frame:
Day 2 through Day 28
Reported as:
Number · participants
Number of Participants That Died on or Before Day 28 (Mortality)
participantsImmediate VoriconazoleDeferred Voriconazole Treatment
Number of Participants That Died on or Before Day 28 (Mortality)41
Statistical analysis
  • Immediate Voriconazole vs Deferred Voriconazole Treatment · Difference in % participants that died: 5.85 · 95% CI -5.08 to 16.78Approximate 2-sided confidence interval (CI).
SecondaryTime to Negative Panfungal Polymerase Chain Reaction (PCR)

Time (in days) from start of study medication to negative panfungal PCR; assessed for participants whose most recent panfungal PCR result prior to start of study medication was positive. Defined as negative if at least 2 successive and all following panfungal PCR assessments from start of study medication until 24 hours after end of treatment are negative. Measured as first quartile of time (point in time measurement; no median or measure of dispersion calculated); median time was not estimable for deferred voriconazole treatment group.

Time frame:
Day 2 through Day 28
Reported as:
Number · days
Time to Negative Panfungal Polymerase Chain Reaction (PCR)
daysImmediate VoriconazoleDeferred Voriconazole Treatment
Time to Negative Panfungal Polymerase Chain Reaction (PCR)4.05.5
Statistical analysis
  • Immediate Voriconazole vs Deferred Voriconazole Treatment · Log Rank · p = 0.190
SecondaryCourse of Positive Panfungal PCR Assessments to Explanatory Variables: Association of Positive PCR Assessments With Achievement of Continuous Defervescence (Yes)

Percent of positive panfungal PCR assessments during treatment phase of study in association with achievement of continuous defervescence (response=Yes). Continuous defervescence stated if participant maintains a body temperature of \<38.0 degrees C for at least 96 hours. Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.

Time frame:
Day 2 through Day 28
Reported as:
Mean · percent of positive PCR assessments
Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association of Positive PCR Assessments With Achievement of Continuous Defervescence (Yes)
percent of positive PCR assessmentsImmediate VoriconazoleDeferred Voriconazole Treatment
Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association of Positive PCR Assessments With Achievement of Continuous Defervescence (Yes)10.6 ± 14.118.0 ± 14.71
Statistical analysis
  • Immediate Voriconazole vs Deferred Voriconazole Treatment · Regression, Linear · p = 0.049 (SAS PROC REG with SELECTION=STEPWISE option of SLENTRY=0.05 and SLSTAY=0.10 utilized. Stepwise option combined forward stepping (with a 0.05 level to enter) with elimination of variables already in model that do not stay significant at 0.10 level.) · Mean difference (final values): -22.031 · 95% CI -44.004 to -0.059Variables: association with age, c-reactive protein, and time to continuous defervescence not significant at 0.05 level; not included in final model
SecondaryCourse of Positive Panfungal PCR Assessments to Explanatory Variables: Association of Positive PCR Assessments With Achievement of Continuous Defervescence (No)

Percent of positive panfungal PCR assessments during treatment phase of study in association with achievement of continuous defervescence (response=No). Continuous defervescence stated if participant maintains a body temperature of \<38.0 degrees C for at least 96 hours. Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.

Time frame:
Day 2 through Day 28
Reported as:
Mean · percent of positive PCR assessments
Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association of Positive PCR Assessments With Achievement of Continuous Defervescence (No)
percent of positive PCR assessmentsImmediate VoriconazoleDeferred Voriconazole Treatment
Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association of Positive PCR Assessments With Achievement of Continuous Defervescence (No)21.7 ± 20.21—
SecondaryCourse of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Age

Percent of positive panfungal PCR assessments during treatment phase of study in association with age for participants who completed the study and have a non-missing value for percent of positive panfungal PCR.

Time frame:
Day 2 through Day 28
Reported as:
Mean · percent of positive PCR assessments

No measurements were reported for this outcome.

SecondaryCourse of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Gender

Percent of positive panfungal PCR assessments during treatment phase of study in association with gender (Female or Male). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.

Time frame:
Day 2 through Day 28
Reported as:
Mean · percent of positive PCR assessments
Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Gender
percent of positive PCR assessmentsImmediate VoriconazoleDeferred Voriconazole Treatment
Female (n=21, 12)12.3 ± 14.824.2 ± 10.36
Male (n=18, 15)10.4 ± 14.7511.1 ± 17.16
SecondaryCourse of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Primary Underlying Neoplastic Disease

Percent of positive panfungal PCR assessments during treatment phase of study in association with primary underlying neoplastic disease. Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.

Time frame:
Day 2 through Day 28
Reported as:
Mean · percent of positive PCR assessments
Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Primary Underlying Neoplastic Disease
percent of positive PCR assessmentsImmediate VoriconazoleDeferred Voriconazole Treatment
Acute lymphatic leukemia (n=6, 6)13.9 ± 16.399.7 ± 15.29
Acute myeloid leukemia (n=29, 18)10.5 ± 14.398.8 ± 15.78
SecondaryCourse of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Planned Allogeneic Transplants

Percent of positive panfungal PCR assessments during treatment phase of study in association with allogeneic bone marrow transplant or allogeneic peripheral stem cell transplant (Yes or No). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.

Time frame:
Day 2 through Day 28
Reported as:
Mean · percent of positive PCR assessments
Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Planned Allogeneic Transplants
percent of positive PCR assessmentsImmediate VoriconazoleDeferred Voriconazole Treatment
Association Yes (n=13, 9)10.5 ± 14.886.5 ± 13.03
Association No (n=26, 18)11.9 ± 14.778.8 ± 15.78
SecondaryCourse of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Concomitant Fluconazole

Percent positive panfungal PCR assessments during treatment phase of study in association with use of concomitant (prophylaxis) fluconazole (Yes or No). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.

Time frame:
Day 2 through Day 28
Reported as:
Mean · percent of positive PCR assessments
Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Concomitant Fluconazole
percent of positive PCR assessmentsImmediate VoriconazoleDeferred Voriconazole Treatment
Association Yes (n=8, 4)13.5 ± 15.396.3 ± 12.50
Association No (n=31, 23)10.9 ± 14.638.3 ± 15.28
SecondaryCourse of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Neutrophil Count >500 uL

Percent of positive panfungal PCR assessments during treatment phase of study in association with neutrophil count \>500 uL (Yes or No). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.

Time frame:
Day 2 through Day 28
Reported as:
Mean · percent of positive PCR assessments
Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Neutrophil Count >500 uL
percent of positive PCR assessmentsImmediate VoriconazoleDeferred Voriconazole Treatment
Association Yes (n=24, 20)10.9 ± 14.607.9 ± 15.17
Association No (n=15, 7)12.3 ± 15.138.3 ± 14.43
SecondaryCourse of Positive Panfungal PCR Assessments to Explanatory Variables: Association With C-reactive Protein Level >1.25 Times the Upper Limit of Normal (x ULN)

Percent of positive panfungal PCR assessments during treatment phase of study in association with c-reactive protein level (measured in milligrams per liter \[mg/L\]) \>1.25 x ULN (Yes or No). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.

Time frame:
Day 2 through Day 28
Reported as:
Mean · percent of positive PCR assessments

No measurements were reported for this outcome.

SecondaryCourse of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Fungal Species Identified

Percent of positive panfungal PCR assessments during treatment phase of study in association with fungal species (singular \[one species\]=sp; plural \[many species\]=spp) identified (Yes or No). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.

Time frame:
Day 2 through Day 28
Reported as:
Mean · percent of positive PCR assessments
Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Fungal Species Identified
percent of positive PCR assessmentsImmediate VoriconazoleDeferred Voriconazole Treatment
Aspergillus flavus: No (n=39, 27)11.4 ± 14.628.0 ± 14.71
Aspergillus fumig: No (n=38, 27)11.7 ± 14.708.0 ± 14.71
Aspergillus nidulans: No (n=39, 27)11.4 ± 14.628.0 ± 14.71
Aspergillus sp: No (n=39, 27)11.4 ± 14.628.0 ± 14.71
Aspergillus spp: No (n=37, 27)11.6 ± 14.888.0 ± 14.71
Candida albicans: Yes (n=2, 4)16.7 ± 23.570.0 ± 0.0
Candida albicans: No (n=37, 23)11.2 ± 14.459.4 ± 15.55
Candida glabrata: Yes (n=2, 1)33.3 ± 0.000.0 ± 0.0
Candida glabrata: No (n=37, 26)10.3 ± 14.068.3 ± 14.91
Candida krusei: No (n=39, 26)11.4 ± 14.628.3 ± 14.91
Candida spp: No (n=38, 27)11.7 ± 14.708.0 ± 14.71
Candida tropicalis: No (n=39, 27)11.4 ± 14.628.0 ± 14.71
SecondaryCourse of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Fungal Species Identified (Aspergillus Spp=Yes)

Percent of positive panfungal PCR assessments during treatment phase of study in association with fungal species (singular \[one species\]=sp; plural \[many species\]=spp) identified (Yes). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.

Time frame:
Day 2 through Day 28
Reported as:
Mean · percent of positive PCR assessments
Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Fungal Species Identified (Aspergillus Spp=Yes)
percent of positive PCR assessmentsImmediate VoriconazoleDeferred Voriconazole Treatment
Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Fungal Species Identified (Aspergillus Spp=Yes)8.3 ± 11.79—
SecondaryCourse of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Proven or Probable IFI (Complete Cases) Between Day 2 and Day 28

Percent of positive panfungal PCR assessments during treatment phase of study in association with proven or probable IFI (complete cases) between Day 2 and Day 28 (Yes or No). Complete case analysis: participant must be evaluable until Day 28 (final visit) or have developed a proven or probable IFI by the final visit. Participant considered evaluable until Day 28 if participant completed the study and completed an assessment of IFI at Day 28 or final visit. Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.

Time frame:
Day 2 through Day 28
Reported as:
Mean · percent of positive PCR assessments
Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Proven or Probable IFI (Complete Cases) Between Day 2 and Day 28
percent of positive PCR assessmentsImmediate VoriconazoleDeferred Voriconazole Treatment
Association Yes (n=2, 2)0.0 ± 0.016.7 ± 23.57
Association No (n=37, 25)12.1 ± 14.777.3 ± 14.30
SecondaryCourse of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Defervescence Day 5 (4 Days After Initiation of Study Treatment)

Percent of positive panfungal PCR assessments during treatment phase of study in association with defervescence (were afebrile) Day 5 (Yes or No). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.

Time frame:
Day 5 (96 hours through 120 hours after start of study treatment)
Reported as:
Mean · percent of positive PCR assessments
Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Defervescence Day 5 (4 Days After Initiation of Study Treatment)
percent of positive PCR assessmentsImmediate VoriconazoleDeferred Voricoazole Treatment
Association Yes (n=28, 21)14.5 ± 14.588.3 ± 15.81
Association No (n=11, 6)3.6 ± 12.066.9 ± 11.08
SecondaryCourse of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Defervescence (Yes) by Day 9 (8 Days After Initiation of Study Treatment)

Percent of positive panfungal PCR assessments during treatment phase of study in association with defervescence (were afebrile) Day 9 (Yes). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.

Time frame:
Day 2 through Day 9 (192 hours through 216 hours after start of study treatment)
Reported as:
Mean · percent of positive PCR assessments
Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Defervescence (Yes) by Day 9 (8 Days After Initiation of Study Treatment)
percent of positive PCR assessmentsImmediate VoriconazoleDeferred Voriconazole Treatment
Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Defervescence (Yes) by Day 9 (8 Days After Initiation of Study Treatment)11.0 ± 14.118.0 ± 14.71
SecondaryCourse of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Defervescence (No) by Day 9 (8 Days After Initiation of Study Treatment)

Percent of positive panfungal PCR assessments during treatment phase of study in association with defervescence (were afebrile) Day 9 (No). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.

Time frame:
Day 2 through Day 9 (192 hours through 216 hours after start of study treatment)
Reported as:
Mean · percent of positive PCR assessments
Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Defervescence (No) by Day 9 (8 Days After Initiation of Study Treatment)
percent of positive PCR assessmentsImmediate VoriconazoleDeferred Voriconazole Treatment
Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Defervescence (No) by Day 9 (8 Days After Initiation of Study Treatment)20.0 ± 28.28—
SecondaryCourse of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Time to Defervescence

Percent of positive panfungal PCR assessments during treatment phase of study in association with time to defervescence. Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.

Time frame:
Day 2 through Day 28
Reported as:
Mean · percent of positive PCR assessments

No measurements were reported for this outcome.

SecondaryCourse of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Reasons for Lack of Continuous Defervescence (No)

Percent of positive panfungal PCR assessments during treatment phase of study in association with lack of continuous defervescence (No). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.

Time frame:
Day 2 through Day 28
Reported as:
Mean · percent of positive PCR assessments
Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Reasons for Lack of Continuous Defervescence (No)
percent of positive PCR assessmentsImmediate VoriconazoleDeferred Voriconazole Treatment
Fungal infection: No (n=39, 27)11.4 ± 14.628.0 ± 14.71
Bacterial infection: No (n=39, 27)11.4 ± 14.628.0 ± 14.71
Viral infection: No (n=39, 27)11.4 ± 14.628.0 ± 14.71
Unknown infection: No (n=36, 27)10.6 ± 14.118.0 ± 14.71
Other infection: No (n=39, 27)11.4 ± 14.628.0 ± 14.71
SecondaryCourse of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Reasons for Lack of Continuous Defervescence: Unknown Infection (Yes)

Percent of positive panfungal PCR assessments during treatment phase of study in association with lack of continuous defervescence (Yes). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.

Time frame:
Day 2 through Day 28
Reported as:
Mean · percent of positive PCR assessments
Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Reasons for Lack of Continuous Defervescence: Unknown Infection (Yes)
percent of positive PCR assessmentsImmediate VoriconazoleDeferred Voriconazole Treatment
Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Reasons for Lack of Continuous Defervescence: Unknown Infection (Yes)21.7 ± 20.21—
SecondaryCourse of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Mortality by Day 28 (Alive)

Percent of positive panfungal PCR assessments during treatment phase of study in association with mortality on or before Day 28 after start of study treatment (Alive). A participant must be evaluable until Day 28 (final visit).

Time frame:
Day 2 through Day 28
Reported as:
Mean · percent of positive PCR assessments
Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Mortality by Day 28 (Alive)
percent of positive PCR assessmentsImmediate VoriconazoleDeferred Voriconazole Treatment
Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Mortality by Day 28 (Alive)11.4 ± 14.628.0 ± 14.71
SecondaryCourse of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Mortality by Day 28 (Died)

Percent of positive panfungal PCR assessments during treatment phase of study in association with mortality on or before Day 28 after start of study treatment (Died). A participant must have died before Day 28 (final visit).

Time frame:
Day 2 through Day 28
Reported as:
Number · percent of positive PCR assessments

No measurements were reported for this outcome.

SecondaryNumber of Participants Assessed as Needing Further Antineoplastic Therapy as Planned
Time frame:
Day 28
Reported as:
Number · participants
Number of Participants Assessed as Needing Further Antineoplastic Therapy as Planned
participantsImmediate VoriconazoleDeferred Voriconazole Treatment
Number of Participants Assessed as Needing Further Antineoplastic Therapy as Planned4232
Statistical analysis
  • Immediate Voriconazole vs Deferred Voriconazole Treatment · Difference in percentages: 2.51 · 95% CI -14.96 to 19.97
SecondaryNumber of Participants With Reasons Why Antineoplastic Therapy Not Continued as Planned
Time frame:
Day 28
Reported as:
Number · participants

No measurements were reported for this outcome.

Adverse events

Collected over Baseline up to 7 days after last dose of study drug. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Immediate Voriconazole—8/81 (9.9%)58/81 (71.6%)
Deferred Voriconazole Treatment—8/66 (12.1%)38/66 (57.6%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventImmediate VoriconazoleDeferred Voriconazole Treatment
SepsisInfections and infestations1/812/66
Gastrointestinal haemorrhageGastrointestinal disorders1/811/66
Chest painGeneral disorders0/811/66
PyrexiaGeneral disorders0/811/66
Hepatic function abnormalHepatobiliary disorders0/811/66
Bacterial sepsisInfections and infestations0/811/66
CellulitisInfections and infestations0/811/66
Encephalitic infectionInfections and infestations0/811/66
Enterocolitis bacterialInfections and infestations0/811/66
Gastroenteritis norovirusInfections and infestations0/811/66
Most frequent other events
Showing 10 of 19
Most frequent other events
EventImmediate VoriconazoleDeferred Voriconazole Treatment
DiarrhoeaGastrointestinal disorders22/8113/66
RashSkin and subcutaneous tissue disorders14/816/66
HeadacheNervous system disorders8/8111/66
NauseaGastrointestinal disorders12/816/66
EpistaxisRespiratory, thoracic and mediastinal disorders11/814/66
VomitingGastrointestinal disorders9/815/66
HypokalaemiaMetabolism and nutrition disorders8/812/66
ConstipationGastrointestinal disorders7/813/66
Mucosal inflammationGeneral disorders7/813/66
PyrexiaGeneral disorders7/815/66

Baseline characteristics

Age, Customized
Age, Customized(participants)Immediate VoriconazoleDeferred Voriconazole TreatmentTotal
Between 18 and 44 years291746
Between 45 and 64 years313566
>=65 years211435
Sex: Female, Male
Sex: Female, Male(Participants)Immediate VoriconazoleDeferred Voriconazole TreatmentTotal
Female392968
Male423779
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Immediate VoriconazoleDeferred Voriconazole TreatmentTotal
White8165146
Other011
Weight
Weight(kilograms (kg))Immediate VoriconazoleDeferred Voriconazole TreatmentTotal
Mean77.1 (42.0 to 112.5)79.2 (45.3 to 152.0)78.1 (42.0 to 152.0)
Height
Height(centimeters (cm))Immediate VoriconazoleDeferred Voriconazole TreatmentTotal
Mean172.1 (150.0 to 196.0)171.9 (153.0 to 198.0)172.0 (150.0 to 198.0)
08

Study locations

28 sites
  • Pfizer Investigational Site
    Augsburg, 86156, Germany
  • Pfizer Investigational Site
    Berlin, 10117, Germany
  • Pfizer Investigational Site
    Berlin, 12200, Germany
  • Pfizer Investigational Site
    Berlin, 13353, Germany
  • Pfizer Investigational Site
    Bielefeld, 33611, Germany
  • Pfizer Investigational Site
    Bremen, 28177, Germany
  • Pfizer Investigational Site
    Chemnitz, 09113, Germany
  • Pfizer Investigational Site
    Dresden, 01307, Germany
  • Pfizer Investigational Site
    Erlangen, 91054, Germany
  • Pfizer Investigational Site
    Essen, 45239, Germany
  • Pfizer Investigational Site
    Frankfurt (Oder), 15236, Germany
  • Pfizer Investigational Site
    Freiburg, 79106, Germany
  • Pfizer Investigational Site
    Goettingen, 37075, Germany
  • Pfizer Investigational Site
    Hannover, 30623, Germany
  • Pfizer Investigational Site
    Homburg/Saar, 66421, Germany
  • Pfizer Investigational Site
    Kiel, 24116, Germany
  • Pfizer Investigational Site
    Koeln, 50937, Germany
  • Pfizer Investigational Site
    Leipzig, 04103, Germany
  • Pfizer Investigational Site
    Ludwigshafen, 67063, Germany
  • Pfizer Investigational Site
    Luebeck, 23538, Germany
  • Pfizer Investigational Site
    Mainz, 55101, Germany
  • Pfizer Investigational Site
    Muenchen, 81675, Germany
  • Pfizer Investigational Site
    Muenchen, 81737, Germany
  • Pfizer Investigational Site
    Potsdam, 14467, Germany
  • Pfizer Investigational Site
    Stuttgart, 70376, Germany
  • Pfizer Investigational Site
    Trier, 54290, Germany
  • Pfizer Investigational Site
    Wiesbaden, 65191, Germany
  • Pfizer Investigational Site
    Wuerzburg, 97070, Germany
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2005, a primary completion of Apr 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2010, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2005
First posted
Sep 8, 2005
Start
Jan 2005
Primary completionActual
Apr 2009
CompletionActual
Apr 2009
Results first posted
Aug 18, 2010
Last update
Jan 19, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 19, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00150345
Lead sponsor
Pfizer
Collaborators
Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
Responsible party
Sponsor
First posted
Sep 8, 2005
Start date
Jan 2005
Primary completion
Apr 2009
Completion
Apr 2009
Results posted
Aug 18, 2010
Last update
Jan 19, 2012

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Voriconazole

Start the discussion